Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-06-29
2008-10-21
Saunders, David A. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S389300, C530S387300, C424S130100, C424S146100, C424S158100
Reexamination Certificate
active
07439331
ABSTRACT:
The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
REFERENCES:
patent: 5456909 (1995-10-01), March, Jr. et al.
patent: 5624837 (1997-04-01), Fodor et al.
patent: 5627264 (1997-05-01), Fodor et al.
patent: 5679546 (1997-10-01), Ko et al.
patent: 5851528 (1998-12-01), Ko et al.
patent: 5853722 (1998-12-01), Rollins et al.
patent: 5856297 (1999-01-01), Fearon et al.
patent: 5856300 (1999-01-01), Rittershaws et al.
patent: 5858969 (1999-01-01), Marsh, Jr. et al.
patent: 5861156 (1999-01-01), George et al.
patent: 6956107 (2005-10-01), Fung et al.
patent: 7112327 (2006-09-01), Fung et al.
patent: WO 95/29697 (1995-11-01), None
Janeway, C. et al. Immunobiology, 3rd edition, Current Biology Ltd, London, England 1997 p. 13:7-8.
Klohs, Wayne D., et al., “Inhibitors of Tyrosine Kinase”,Current Opinion in Oncology, vol. 9, pp. 562-568 (1997).
Stadel, Jeffrey, et al., “Orphan G Protein-Coupled Receptors—A Neglected Opportunity for Pioneer Drug Discovery”,TiPS, vol. 18, pp. 430-437 (1997).
Strawn, Laurie, et al., “FLK-1 as Target Tumor Growth Inhibition”,Cancer Research, vol. 56, pp. 3540-3545 (1996).
Abhijit, Ray, et al., “Thrombin Receptor: A Novel Target for Antiplatelet Drug Development”,Thrombosis Research, vol. 87, No. 1, pp. 37-50 (1997).
Sato, Toshiro, et al., “A New Method for Studying a Binding of Human IgE to CD23 and the Inhibition of this Binding”,Journal of Immunological Methods, vol. 209, pp. 59-66 (1997).
Bertozzi, C. R. Carolyn, et al., “An ELISA for Selectins Based on Binding to a Physiological Ligand”,Journal of Immunological Methods, vol. 203, pp. 157-165 (1997).
Gao, Jingbo, et al., “An Enzyme-Linked Immunosorbert Assay to Identify Inhibitors of Activation of Platelet Intergrin αllbβ3”Journal of Immunological Methods, vol. 181, pp. 55-64 (1995).
Wilson, Anne B., et al., “A Competitive Inhibition ELISA for the Quantification of Human Interferon-γ”,Journal of Immunological Methods, vol. 162, pp. 247-255 (1993).
Pascual, Manuel, et al., “A Monoclonal Antibody Which Blocks the Function of Factor D of Human Complement”,Journal of Immunological Methods, vol. 127, pp. 263-269 (1990).
Pascual, Manuel, et al., “Inhibition of Complement Alternative Pathway in Mice with Fab Antibody to Recombinant Adipsin/Factor D”,Euro. J. Immunol., vol. 23, pp. 1389-1392 (1993).
Omer, Charles, et al., “CA1A2x-Competitive Inhibitors of Farnesyltransferase as Anti-Cancer Agents”,TiPS, vol. 18, pp. 437-443 (1997).
Lam, Kits, et al., “Application of Combinatorial Library Methods in Cancer Research and Drug Discovery”,Anti-Cancer Drug Design, vol. 12, pp. 145-167 (1997).
Tanhehco, E. J., et al., “The Anti-Factor D Antibody, MAb 166-32, Inhibits the Alternative Pathway of the Human Complement System”,Transplantation Proceedings, vol. 31, pp. 2168-2171 (1999).
Houghten, R. A., et al., “The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides”,Biotechniques, vol. 13, No. 3, pp. 412-421 (1992).
Huber-Lang, Markus, et al., “Role of C5a in Multiorgan Failure During Sepsis”Journal of Immunology, vol. 166, pp. 1193-1198, (2001).
Sim, R. B., et al., “Serine Proteases of the Complement System”,Biochemical Society Transactions, vol. 28, Pt. 5, pp. 545-550 (2000).
Kroshus, T. J., et al., “Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-to-Human Xenotransplantation”,Transplantation, vol. 60, pp. 1194-1202 (1995).
Volkanakis, John E., et al., “Complement Factor D, A Novel Serine Protease”,Protein Science, vol. 5, pp. 553-564 (1996).
Niemann, Marilyn A., et al., “The Use of Monoclonal Antibodies as Probes of the Three Dimensional Structure of Human Complement Factor D”,J. Immunol., vol. 132, No. 2, pp. 809-815 (1984).
Evans, Mark J., et al., Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector that Replicates in COS and 293 Cells,J. Immunol., vol. 184, pp. 123-138 (1995).
Rabinovici, Reuven, et al., “Role of Complement in Endotoxin/Platelet-Activating: Factor-Induced Lung Injury”,J. Immunol., vol. 149, No. 5, pp. 1744-1750 (1992).
White, R. Tyler, et al., “Human Adipsin is Identical to Complement Factor D and is Expressed at High Levels in Adipose Tissue”,J. Biology, vol. 267, No. 13, pp. 9210-9213 (1992).
Narayana, Sthanam, et al., “Structure of Human Factor D:A Complement System Protein at 20° Resolution”,J. Mol. Biol., vol. 235, pp. 695-708 (1994).
Rider, Christine S., et al., “Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation During Extracoporeal Circulation”,J. Clin. Invest., vol. 96, pp. 1564-1572 (1995).
Lesavre, Phillipe H., et al., “Mechanism of Action of Factor D of the Alternative Complement Pathway”,J. Exp. Med., vol. 148, pp. 1498-1509 (Dec. 1978).
Homeister, Jonathon, et al., “Soluble Complement Receptor Type I Prevents Human Complement-Medicated Damage of the Rabbit Isolated Heart”,The Journal of Immunology, vol. 150, No. 3, pp. 1055-1064 (1993).
Amsterdam, Ezra A., et al., “Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a During Myocardial Infarction in Pigs”,Am. J. Physiol., vol. 268, pp. H448-H457 (1995).
Wang, Yi, et al., “Anti-C5 Monoclonal Antibody Therapy Prevents Collagen-Induced Arthritis and Ameliorates Established Disease”,Proc. Natl. Acad. Sci, USA, vol. 92, pp. 8955-8959 (1995).
Weismann, Harlan F., et al., “Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Supressing Post-Ischemic Myocardial Inflammation and Necrosis”,Science, vol. 249, pp. 146-151 (1990).
Mulligan, Michael S., et al., “Protective Effects of Soluble CR1 in Complement and Neutrophil-Medicated Tissue Injury”,J. Immunol., vol. 148, No. 5, pp. 1479-1485 (1992).
Morgan, B. P., et al., “Clinical Complementology: Recent Progress and Future Trends”,European Journal of Clinical Investigation, vol. 24, pp. 219-228 (1994).
Wang, Y., et al., “Amelioration of Lupus-Like Autoimmune Disease in NZB/W F1Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5”,Nat'l. Acad. Sci. USA, vol. 93, pp. 8563-8568 (1996).
Holers, Michael V., et al., “Complement”, In:Host Defense Mechanism and Inflammation, Chapter 24, pp. 363-391.
Volonakis, et al., “Complement Enzymes”, In:The Human Complement System in Health&Disease, Chapter 4, Ed., J. Volonakis & M. M. Frank.
Fung, M., et al., “Inhibition of Complement, Neutrophil, and Platelet Activation by an Anti-Factor D Antibody During Extracorporeal Circulation”, Presented in the 18thAnnual Houston Conference on Biomedical Engineering Research, Houston, Texas, Feb. 10-11, 2000, (Abstract).
Ündar, A., et al., Novel Anti-Factor D Monoclonal Antibody Inhibits Complement, Neutrophil, and Platelet Activation in a Simulated Pediatric Cardiopulmonary Bypass Circuit., Presented in the 46thAnnual Conference of the American Society for Artificial Internal Organs, New York, N.Y., Jun. 28-Jul. 1, 2000, (Abstr
Fung Michael S. C.
Sun Cecily R. Y.
Sun William N. C.
Genentech Inc.
Jones Day
Saunders David A.
VanderVegt F. Pierre
LandOfFree
Inhibition of complement activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of complement activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of complement activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4003595